Merck & Co., Inc. (NYSE:MRK) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 10:00 AM ET
Company Participants
Dean Y. Li – Executive VP & President of Merck Research Laboratories
Robert M. Davis – Chairman, President & CEO
Unidentified Analyst
Let’s get started. Very excited to welcome Merck to our next session, Rob Davis, Chairman and CEO; Dean Li, EVP and President of Merck Research Labs. Welcome, Rob and Dean.
Robert M. Davis
Great. Thanks for having us.
Unidentified Analyst
So Rob, there’s obviously a lot to talk about. There’s been a lot of news flow over the last 24 hours that impacts Merck both directly and indirectly. But before we start double-clicking on some of that, maybe I can just hand it over to you to make some high-level comments.
Robert M. Davis
Yes. No, happy to do, and thank you, and thank you for everyone in attendance and listening. Obviously, it’s an interesting time in the broader world. But if you focus in on where we are at Merck, I can tell you, we are very excited about what we have in front of us. We’re really in a period of transformation. You saw yesterday, we had 2 important announcements. We announced 2 of our 3 Phase III study readouts for enlicitide, our oral PCSK9 with really good results there. We received the approval, the FDA approval of clesrovimab, our RSV vaccine. And really, this is just the beginning of what’s going to be a period of data readouts and product launches.
As you look forward now, we actually have nearly 20 new assets. We have 20 if you would include the ongoing launches of WINREVAIR and [indiscernible] that are both actually off to strong starts, nearly 20 additional launches of new assets coming over the next few years, which is really
Read the full article here